Skip to content

Study · Randomized controlled trial · n = 34 · 1998

5 results

Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results.

Moscarella S, Buzzelli G, Romanelli RG, Monti M, Giannini C, Careccia G, Marrocchi EM, Zignego AL

Liver1 Oct 1998Cited by 24 (Europe PMC)

PMID9831367 (opens in a new tab)DOI10.1111/j.1600-0676.1998.tb00819.x (opens in a new tab)PepBankPUB-09831367
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In naive patients with chronic hepatitis C, thymosin alpha‑1 plus interferon-alpha gave a significantly higher end-of-treatment biochemical response than interferon-alpha alone.

    In plain wordsIn people with chronic hepatitis C, thymosin alpha‑1 plus interferon gave better liver enzyme response at the end of treatment than interferon alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseEnd-of-treatment biochemical response
    Study

    n = 34

    Comparator
    Interferon alpha-2b alone
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1 mg twice weekly · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Combination therapy showed significantly higher efficacy than monotherapy in achieving biochemical and virologic end-of-treatment response (p<0.05).
    2 context sentences
    Summary · context
    Seventeen patients were treated with IFN alpha-2b (3 million units MU three times a week) + Talpha1 (1 mg twice weekly); the other 17 patients received only IFN alpha-2b at the same dose.
    Summary · context
    All patients were treated for 6 months and followed up for 12 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In naive patients with chronic hepatitis C, thymosin alpha‑1 plus interferon-alpha gave a significantly higher end-of-treatment virologic response than interferon-alpha alone.

    In plain wordsIn people with chronic hepatitis C, thymosin alpha‑1 plus interferon gave better virus response at the end of treatment than interferon alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseEnd-of-treatment virologic response
    Study

    n = 34

    Comparator
    Interferon alpha-2b alone
    Outcome group
    Antiviral activity · Liver
    Studied dose
    1 mg twice weekly · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Combination therapy showed significantly higher efficacy than monotherapy in achieving biochemical and virologic end-of-treatment response (p<0.05).
    2 context sentences
    Summary · context
    Seventeen patients were treated with IFN alpha-2b (3 million units MU three times a week) + Talpha1 (1 mg twice weekly); the other 17 patients received only IFN alpha-2b at the same dose.
    Summary · context
    All patients were treated for 6 months and followed up for 12 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In naive patients with chronic hepatitis C, sustained biochemical response at 12-month follow-up was slightly greater with combination therapy than with interferon-alpha alone; no significance is stated.

    In plain wordsIn people with chronic hepatitis C, lasting liver enzyme response at 12 months was slightly greater with thymosin alpha‑1 plus interferon than interferon alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSustained biochemical response at 12-month follow-up
    Study

    n = 34

    Comparator
    Interferon alpha-2b alone
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1 mg twice weekly · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    At 12 month follow-up, the sustained biochemical response was slightly greater in patients treated with combination therapy than in those treated with monotherapy.
    2 context sentences
    Summary · context
    Seventeen patients were treated with IFN alpha-2b (3 million units MU three times a week) + Talpha1 (1 mg twice weekly); the other 17 patients received only IFN alpha-2b at the same dose.
    Summary · context
    All patients were treated for 6 months and followed up for 12 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In naive patients with chronic hepatitis C of subtype HCV-1b, response did not differ significantly between combination therapy and interferon-alpha alone.

    In plain wordsIn people with chronic hepatitis C of subtype 1b, response was not significantly different between thymosin alpha‑1 plus interferon and interferon alone.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeResponse in HCV-1b subtype
    Study

    n: not reported in source

    Comparator
    Interferon alpha-2b alone
    Outcome group
    Antiviral activity · Liver
    Studied dose
    1 mg twice weekly · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    No significant difference in response by HCV-1b subtype was observed between the two treatment groups
    2 context sentences
    Summary · context
    Seventeen patients were treated with IFN alpha-2b (3 million units MU three times a week) + Talpha1 (1 mg twice weekly); the other 17 patients received only IFN alpha-2b at the same dose.
    Summary · context
    All patients were treated for 6 months and followed up for 12 months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In naive patients with chronic hepatitis C of subtype HCV-2c, there was a trend toward a better response with combination therapy than with interferon-alpha alone.

    In plain wordsIn people with chronic hepatitis C of subtype 2c, there was a trend toward better response with thymosin alpha‑1 plus interferon than interferon alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseResponse in HCV-2c subtype
    Study

    n: not reported in source

    Comparator
    Interferon alpha-2b alone
    Outcome group
    Antiviral activity · Liver
    Studied dose
    1 mg twice weekly · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    HCV-2c subtype showed a trend to responding better to IFN-alpha+Talpha1 than to IFN-alpha alone.
    2 context sentences
    Summary · context
    Seventeen patients were treated with IFN alpha-2b (3 million units MU three times a week) + Talpha1 (1 mg twice weekly); the other 17 patients received only IFN alpha-2b at the same dose.
    Summary · context
    All patients were treated for 6 months and followed up for 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.